Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30995379 | 1.00 | GPR119 (0.37) | GPR119ACHETLR9LMNAMAPT | |
| SCHEMBL27213776 | 0.90 | TLR9 (0.37) | GPR119ACHETLR9LMNAMAPT | |
| SCHEMBL30995287 | 0.90 | TLR9 (0.37) | GPR119ACHETLR9LMNAMAPT | |
| SCHEMBL29318390 | 0.90 | TLR9 (0.37) | GPR119ACHETLR9LMNAMAPT | |
| SCHEMBL29319429 | 0.87 | ACHE (0.37) | GPR119ACHETLR9LMNAMAPT | |
| SCHEMBL30995409 | 0.87 | ACHE (0.37) | GPR119ACHETLR9LMNAMAPT | |
| SCHEMBL30995325 | 0.86 | TLR9 (0.37) | GPR119ACHETLR9LMNAMAPT | |
| SCHEMBL29319797 | 0.84 | P2RX7 (0.36) | SMN1; SMN2 | |
| SCHEMBL30995420 | 0.84 | P2RX7 (0.36) | SMN1; SMN2 | |
| SCHEMBL30849234 | 0.81 | CA2 (0.32) | LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | GPR119 496/4885ACHE 4139/4885TLR9 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.